[go: up one dir, main page]

HUP0300900A3 - Polymorphic forms of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, process for their preparation and their use - Google Patents

Polymorphic forms of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, process for their preparation and their use

Info

Publication number
HUP0300900A3
HUP0300900A3 HU0300900A HUP0300900A HUP0300900A3 HU P0300900 A3 HUP0300900 A3 HU P0300900A3 HU 0300900 A HU0300900 A HU 0300900A HU P0300900 A HUP0300900 A HU P0300900A HU P0300900 A3 HUP0300900 A3 HU P0300900A3
Authority
HU
Hungary
Prior art keywords
ylpropoxy
fluorophenylamino
quinazolin
morpholin
chloro
Prior art date
Application number
HU0300900A
Other languages
English (en)
Original Assignee
Goedecke Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goedecke Gmbh filed Critical Goedecke Gmbh
Publication of HUP0300900A2 publication Critical patent/HUP0300900A2/hu
Publication of HUP0300900A3 publication Critical patent/HUP0300900A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HU0300900A 2000-06-30 2001-06-15 Polymorphic forms of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, process for their preparation and their use HUP0300900A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10031971A DE10031971A1 (de) 2000-06-30 2000-06-30 Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung
PCT/EP2001/006733 WO2002000630A1 (en) 2000-06-30 2001-06-15 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride

Publications (2)

Publication Number Publication Date
HUP0300900A2 HUP0300900A2 (hu) 2003-10-28
HUP0300900A3 true HUP0300900A3 (en) 2004-01-28

Family

ID=7647397

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300900A HUP0300900A3 (en) 2000-06-30 2001-06-15 Polymorphic forms of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, process for their preparation and their use

Country Status (39)

Country Link
US (1) US20040034022A1 (hu)
EP (1) EP1299363A1 (hu)
JP (1) JP2004501902A (hu)
KR (1) KR20030014403A (hu)
CN (1) CN1438994A (hu)
AP (1) AP2002002694A0 (hu)
AR (1) AR031854A1 (hu)
AU (1) AU2001283861A1 (hu)
BG (1) BG107352A (hu)
BR (1) BR0112082A (hu)
CA (1) CA2412535A1 (hu)
CZ (1) CZ20024037A3 (hu)
DE (1) DE10031971A1 (hu)
DZ (1) DZ3342A1 (hu)
EA (1) EA005294B1 (hu)
EC (1) ECSP024413A (hu)
EE (1) EE200200714A (hu)
GT (1) GT200100124A (hu)
HN (1) HN2001000134A (hu)
HR (1) HRP20021019A2 (hu)
HU (1) HUP0300900A3 (hu)
IL (1) IL152419A0 (hu)
IS (1) IS6596A (hu)
MA (1) MA26924A1 (hu)
MX (1) MXPA03000101A (hu)
NO (1) NO20026193L (hu)
NZ (1) NZ522001A (hu)
OA (1) OA12301A (hu)
PA (1) PA8520801A1 (hu)
PE (1) PE20020116A1 (hu)
PL (1) PL365127A1 (hu)
SK (1) SK17642002A3 (hu)
SV (1) SV2002000517A (hu)
TN (1) TNSN01090A1 (hu)
UA (1) UA73588C2 (hu)
UY (1) UY26803A1 (hu)
WO (1) WO2002000630A1 (hu)
YU (1) YU99802A (hu)
ZA (1) ZA200209717B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
DE102006000122A1 (de) * 2006-03-17 2007-09-20 Aug. Winkhaus Gmbh & Co. Kg Schlüssel für einen Schließzylinder und Schließzylinder für einen solchen Schlüssel
JP6674027B2 (ja) * 2015-12-25 2020-04-01 シュアンチュー ファーマ カンパニー，リミティド キナゾリン誘導体の結晶及びその調製方法
WO2017107985A1 (zh) * 2015-12-25 2017-06-29 山东轩竹医药科技有限公司 喹唑啉衍生物的晶体及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213730T1 (de) * 1996-04-12 2002-03-15 Warner Lambert Co Umkehrbare inhibitoren von tyrosin kinasen
AU763626B2 (en) * 1998-11-19 2003-07-31 Warner-Lambert Company N-(4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl- propoxy)-quinazolin-6-yl)-acrylamide, an irreversible inhibitor of tyrosine kinases

Also Published As

Publication number Publication date
GT200100124A (es) 2002-06-27
CN1438994A (zh) 2003-08-27
ZA200209717B (en) 2003-12-01
KR20030014403A (ko) 2003-02-17
IL152419A0 (en) 2003-05-29
UA73588C2 (en) 2005-08-15
HRP20021019A2 (en) 2004-02-29
CA2412535A1 (en) 2002-01-03
MA26924A1 (fr) 2004-12-20
HN2001000134A (es) 2001-09-11
BG107352A (bg) 2003-07-31
BR0112082A (pt) 2003-05-06
DE10031971A1 (de) 2002-01-10
EA200300094A1 (ru) 2003-04-24
IS6596A (is) 2002-10-28
SV2002000517A (es) 2002-07-03
NO20026193L (no) 2003-01-27
YU99802A (sh) 2005-11-28
HUP0300900A2 (hu) 2003-10-28
CZ20024037A3 (cs) 2004-01-14
MXPA03000101A (es) 2004-09-13
AR031854A1 (es) 2003-10-08
TNSN01090A1 (fr) 2005-11-10
PE20020116A1 (es) 2002-02-27
JP2004501902A (ja) 2004-01-22
EE200200714A (et) 2004-08-16
WO2002000630A1 (en) 2002-01-03
OA12301A (en) 2003-11-10
US20040034022A1 (en) 2004-02-19
EA005294B1 (ru) 2004-12-30
ECSP024413A (es) 2003-03-31
DZ3342A1 (fr) 2002-01-03
EP1299363A1 (en) 2003-04-09
NO20026193D0 (no) 2002-12-23
AU2001283861A1 (en) 2002-01-08
AP2002002694A0 (en) 2002-12-31
PA8520801A1 (es) 2003-06-30
PL365127A1 (en) 2004-12-27
NZ522001A (en) 2004-07-30
UY26803A1 (es) 2002-01-31
SK17642002A3 (sk) 2004-05-04

Similar Documents

Publication Publication Date Title
PL347717A1 (en) N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
AP2002002542A0 (en) Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride methods of production and pharmaceutical uses thereof
EP1363602A4 (en) LOCAL ANESTHESIA, AND METHOD OF USE
PL367272A1 (en) Novel substituted benzimidazole dosage forms and method of using same
IL156737A0 (en) Substituted amine derivatives and methods of use
EE200200118A (et) Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine
HUP0302544A3 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
IL143404A0 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
AU2002351397A8 (en) Systems and methods using vasoconstriction for improved thermal treatment of tissues
IL161733A0 (en) Methods and compositions for therapeutic use of rna interference
HUP0301463A3 (en) Process for the preparation of substituted octanoyl amides and the intermediates
PL375977A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
EP1372654A4 (en) QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES
HUP0300900A3 (en) Polymorphic forms of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, process for their preparation and their use
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
PL355799A1 (en) Method of obtaining derivatives of 2-(1-piperazinyl)benzaldehyde and method of obtaining 3-thiomorpholinone
GB0125119D0 (en) Process of preparing paroxetine and intermediates for use therein
AU2002317319A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
GB0127203D0 (en) Paroxetine salt process of preparation and use thereof
GB0122272D0 (en) Method of forming tubular and flat structures
GB0123902D0 (en) Crosslinkable polymer-modified asphalt and its method of preparation
IL165446A0 (en) Polymorphic forms of dihydrochloride salts of cetrizine and processes for preparation thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees